U.S. Breast Cancer Screening and Diagnostic Analysis and Forecast, 2024-2025 & 2030 with Hologic, GE Healthcare, and Siemens Healthineers Leading the $1.55 Billion Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "U.S. Breast Cancer Screening and Diagnostic Market: Analysis and Forecast, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

The U.S. breast cancer screening and diagnostic market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-2030.

The U.S. breast cancer screening and diagnostic market has been witnessing impressive double-digit growth, largely driven by the introduction of advanced technologies. The shift to digital mammography has been rapid, with digital systems now accounting for approximately 90% of all mammography procedures in the U.S. as of 2021. This transition has been supported by research showing that digital mammography has greater sensitivity, especially for younger women and those with dense breast tissue.

The U.S. breast cancer screening and diagnostic market, driven by leading companies such as Hologic, GE Healthcare, and Siemens Healthineers AG, has transformed the landscape of breast cancer detection. By leveraging advanced technologies such as 3-D mammography, and optoacoustic ultrasound, these companies provide a diverse range of diagnostic solutions that enhance early detection and improve accuracy in distinguishing between benign and malignant lesions.

The innovations in the U.S. breast cancer screening market have a significant impact that goes beyond just diagnosing individual cases. Improved screening methods, such as digital breast tomosynthesis (DBT) and advanced MRI, provide important data that inform clinical trials and drug development. This data helps create more effective treatment strategies tailored to the unique characteristics of each patient, which is especially vital in breast cancer, where identifying specific biomarkers can lead to targeted therapies that enhance patient outcomes.

Additionally, incorporating these advanced screening technologies into public health initiatives raises awareness and encourages more people to participate in screening programs. This increase in participation leads to higher rates of early detection and timely intervention, improving individual health and strengthening community health systems by reducing the number of late-stage diagnoses.

As these technologies continue to evolve and regulatory support grows, the influence of the breast cancer screening and diagnostic market in the U.S. becomes even more pronounced. By advancing precision medicine and providing deeper insights into breast cancer, U.S. breast cancer screening and diagnostic market plays a crucial role in transforming healthcare practices and improving patient outcomes across the country.

Digital Breast Tomosynthesis Segment to Dominate the U.S. Breast Cancer Screening and Diagnostic, Image-Based Market (by Technology)

Based on product, the U.S. breast cancer screening and diagnostic, image-based market was led by the digital breast tomosynthesis segment, which held a 49.93% share in 2023. The rising adoption of digital breast tomosynthesis (DBT) reflects a strong demand for advanced breast cancer screening technologies. DBT is particularly effective in improving detection rates for women with dense breast tissue, making it a vital tool for early diagnosis.

This technology helps reduce false-positive results, leading to better patient experiences and outcomes. The growing recognition of DBT's benefits, supported by clinical guidelines and increased patient awareness, drives its integration into standard screening practices, ultimately advancing breast cancer detection and personalized healthcare solutions which in result propelling the growth of U.S. breast cancer screening and diagnostic market.

Key Market Players and Competition Synopsis

• Koninklijke Philips N.V
• Canon Inc
• Planmed Oy
• Siemens Healthineers AG
• GE Healthcare
• FUJIFILM Holdings Corporation
• Hologic, Inc.
• Mammotome, a Danaher Corporation company
• Becton, Dickinson, and Company
• Metaltronica S.p.A

Key Attributes:

Report Attribute	Details
No. of Pages	288
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$1.55 Billion
Forecasted Market Value (USD) by 2030	$2.34 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	United States

Key Topics Covered:

1. Executive Summary

2. Market Definition

3. Key Questions Answered

4. Research Methodology

5. Breast Cancer Overview

5.1 Breast Cancer Incidence (by Age Group)

5.2 Breast Cancer Incidence (by Ethnicity)

5.3 Breast Cancer Incidence (by State)

5.4 Breast Cancer Prevalence (by Age Group)

5.5 Breast Cancer Prevalence (by Ethnicity)

5.6 Breast Cancer Prevalence (by State)

6. Breast Cancer Screening and Diagnosis Guidelines

6.1 American Cancer Society

6.2 NCCN Guidelines

7. U.S. Breast Cancer Screening and Diagnostic, Image-Based Market

7.1 X-Ray

7.2 Ultrasound

7.3 MRI Coils

7.4 Others

8. Breast Biopsy

8.1 Breast Imaging and Biopsy Emerging Trends

8.2 Breast Imaging Insurance Coverage

9. Market Dynamics

9.1 Key Market Drivers

9.2 Key Market Restraints

9.3 Key Market Opportunities

10. U.S. Breast Mammography Market

10.1 Conventional 2D Mammography

10.2 Overview

10.3 Installed base (by State)

10.4 Imaging Volume (by State)

10.5 Facility Count (by State)

10.6 Market Size and Growth Potential by Region

10.7 Conventional 2D Mammography (by End User)

10.8 Competitive Landscape

11. Digital Breast Tomosynthesis

11.1 Overview

11.2 Installed base (by State)

11.3 Imaging Volume (by State)

11.4 Facility Count (by State)

11.5 Market Size and Growth Potential by Region

11.6 Digital Breast Tomosynthesis (by End User)

12. Competitive Landscape

12.1 Hologic, Inc.

12.2 Siemens Healthineers AG

12.3 GE HealthCare Technologies Inc.

12.4 FUJIFILM Holdings Corporation

12.5 Canon Inc

12.6 Metaltronica S.p.A

12.7 Planmed Oy

13. Contrast-Enhanced Digital Mammography

13.1 Overview

13.2 Imaging Volume (by State)

13.3 Facility Count (by State)

13.4 Market Size and Growth Potential by Region

14. Competitive Landscape

14.1 Hologic, Inc.

14.2 Siemens Healthineers AG

14.3 GE HealthCare Technologies Inc.

14.4 FUJIFILM Holdings Corporation

15. U.S. Image-Guided Breast Biopsy Market

15.1 Overview

15.2 Market Size and Growth Potential (by Product)

15.3 Market Size and Growth Potential ( by Region)

15.4 Market Size and Growth Potential (by End User)

15.5 Installed base (by State)

15.6 Biopsy Volume (by State)

15.7 Facility Count (by State)

16. Competitive Landscape

16.1 Hologic, Inc.

16.2 Danaher Corporation (Mammotome)

16.3 Becton, Dickinson and Company

17. Contrast-Enhanced Mammography-Guided Biopsy

For more information about this report visit https://www.researchandmarkets.com/r/d8m13h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.